|
Jun 17
|
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
|
|
May 10
|
argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Is a Surprise Coming for argenx (ARGX) This Earnings Season?
|
|
May 7
|
argenx announces results of Annual General Meeting of Shareholders
|
|
May 7
|
argenx to Present at BofA Securities 2024 Health Care Conference
|
|
May 2
|
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
|
|
Apr 16
|
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
|
|
Mar 29
|
Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4
|
|
Mar 27
|
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
|
|
Mar 26
|
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
|
|
Mar 26
|
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
|
|
Mar 22
|
Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday
|
|
Mar 22
|
Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?
|
|
Mar 21
|
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
|
|
Mar 19
|
Reasons to Invest in argenx (ARGX)
|
|
Mar 7
|
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
|
|
Mar 7
|
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
|
|
Mar 7
|
Should You be Confident in Your Investment in argenx SE (ARGX)?
|
|
Feb 22
|
Argenx Is Tracking Well Above the Industry
|